alexa Tumor Suppressor Gene ARID1A in Cancer: Recent Advances and Future Perspective | OMICS International
ISSN: 2157-2518
Journal of Carcinogenesis & Mutagenesis

Like us on:

Make the best use of Scientific Research and information from our 700+ peer reviewed, Open Access Journals that operates with the help of 50,000+ Editorial Board Members and esteemed reviewers and 1000+ Scientific associations in Medical, Clinical, Pharmaceutical, Engineering, Technology and Management Fields.
Meet Inspiring Speakers and Experts at our 3000+ Global Conferenceseries Events with over 600+ Conferences, 1200+ Symposiums and 1200+ Workshops on
Medical, Pharma, Engineering, Science, Technology and Business

Tumor Suppressor Gene ARID1A in Cancer: Recent Advances and Future Perspective

Nottegar A1, Veronese N2, Solmi M3 and Luchini C1,4*

1Department of Pathology and Public Health, University and Hospital Trust of Verona, Verona, Italy

2Department of Medicine (DIMED), University of Padua, Padua, Italy

3Department of Neuroscineces, University of Padua, Padua, Italy

4Surgical Pathology Unit, Santa Chiara Hospital, Trento, Italy

*Corresponding Author:
Luchini C
Department of Pathology and Public Health University and Hospital Trust of Verona
Piazzale LA Scuro, 10 37134 Verona (VR), Italy
Tel: 00390458124842
Fax: 00390458127136
E-mail: [email protected]

Received date: January 20, 2016 Accepted date: February 25, 2016 Published date: February 29, 2016

Citation: Nottegar A, Veronese N, Solmi M, Luchini C (2016) Tumor Suppressor Gene ARID1A in Cancer: Recent Advances and Future Perspective. J Carinog Mutagene 7:255. doi: 10.4172/2157-2518.100255

Copyright: © 2016 Nottegar A, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

Visit for more related articles at Journal of Carcinogenesis & Mutagenesis


Tumor suppressor gene; ARID1A; Human malignancies; Prognostic genes


Tumor suppressor gene AT-rich interactive domain 1A (ARID1A) is a subunit of the Switch/Sucrose Non-Fermentable (SWI/SNF) chromatin-remodeling complex; it regulates gene expression by controlling gene accessibility [1,2]. Genes involved in epigenetic mechanisms establishing chromatin structure are very often mutated in different cancer types; among these, gynecological and gastrointestinal malignancies play a very important role [3-9]. Particularly, ARID1A shows one of the highest mutation rates among human malignancies [10]. Therefore, there is considerable interest in developing cancer therapeutics that can negatively interact with ARID1A mutational status. A recent report showed a synthetic lethality by targeting EZH2 (enhancer of zeste 2 polycomb repressive complex 2 subunit) histone methyltransferase activity in ARID1Amutated clear cell ovarian cancer, thanks to a small-molecule inhibitor, available and clinically applicable [11]. Its synthetic lethality is associated with inhibition of PI3K (phosphatidylinositol-4,5- bisphosphate 3-kinase catalytic subunit alpha) / AKT (v-akt murine thymoma viral oncogene homolog 1) signaling. Furthermore, there is evidence suggesting that ARID1A-mutated cancer may also be treated by targeting residual SWI/SNF activity, the PI3K/AKT pathway, the tumor immunological microenvironment, stabilizing wild-type p53 and by targeting the DNA damage response [10,12]. About the DNA damage response, a recently developed class of drugs, the poly(ADPribose) polymerase-inhibitors (PARPi), are currently being developed in clinical trials as a targeted treatment, acting on the pathway of DNA repair [13]. PARP-1 is a well-characterized protein in the PARP family: through the base excision repair pathway, it is critical to the repair of single-strand DNA breaks [13-15]. The inhibition of PARP conducts to the accumulation of single-strand breaks, resulting in double-strand breaks. In cells with defective HR (homologous recombination) gene, like the BRCA(Breast Cancer gene)-mutations carriers, PARP inhibition can lead to chromosomal instability, cell cycle arrest and subsequent apoptosis [14]. Recently, similarly to BRCA, also ARID1A mutations have been associated with defects in DNA repair, indicating tumors with such mutations as another possible target of PARPi [15]. Since ARID1A mutations are prognostic significant [12,16-19], further studies and clinical trials are needed to define the possible effects of PARPi on ovarian tumors, not only with BRCA1 (Breast Cancer 1) and BRCA2 (Breast Cancer 2) genes, but also with ARID1A mutations.


Figure 1: The incomplete “sun” of ARID1A-mutated cancers. Some rays of this “sun”, as shown in this figure, have already been discovered, but we need to further investigate ARID1A-mutated cancer to understand the role of many other rays. Tumor immunological microenvironment does not represent an actual ray for now, but it will be the first one to be added, obviously after further investigations.

Noticeably, a recent meta-analysis indicate that loss of ARID1A shortened time to cancer-specific mortality as well as to recurrence of disease, when adjusting for potential confounders, highlighting the importance of the the search of new therapeutic strategies against tumors with its mutation. A very important aim for surgical pathologist and oncologist, towards personalized medicine, is to investigate and to document on the final pathology report all the morphological aspects with a prognostic impact (e.g.: presence of nodal metastasis, extra-nodal extension of nodal metastasis, presence of vascular embolization) [20-24] and all the molecular features (e.g. BRCA mutations, ARID1A mutations) [12,25] that can indicate the prognosis and may address the therapies. To this aim, the most important prognostic genes, as ARID1A, have to be studied in depth.


Select your language of interest to view the total content in your interested language
Post your comment

Share This Article

Article Usage

  • Total views: 9164
  • [From(publication date):
    February-2016 - Jul 21, 2018]
  • Breakdown by view type
  • HTML page views : 9036
  • PDF downloads : 128

Review summary

  1. Thomas SR
    Posted on Jul 14 2016 at 11:34 pm
    This is a nice short communication with much information on ARID1A tumor suppressor gene. The communication is well written and easy to follow for the readers of the journal. Publication of the article will help in the designing suitable therapeutic methods for the treatment of cancer.

Post your comment

captcha   Reload  Can't read the image? click here to refresh

Peer Reviewed Journals
Make the best use of Scientific Research and information from our 700 + peer reviewed, Open Access Journals
International Conferences 2018-19
Meet Inspiring Speakers and Experts at our 3000+ Global Annual Meetings

Contact Us

Agri & Aquaculture Journals

Dr. Krish

[email protected]

+1-702-714-7001Extn: 9040

Biochemistry Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Business & Management Journals


[email protected]

1-702-714-7001Extn: 9042

Chemistry Journals

Gabriel Shaw

[email protected]

1-702-714-7001Extn: 9040

Clinical Journals

Datta A

[email protected]

1-702-714-7001Extn: 9037

Engineering Journals

James Franklin

[email protected]

1-702-714-7001Extn: 9042

Food & Nutrition Journals

Katie Wilson

[email protected]

1-702-714-7001Extn: 9042

General Science

Andrea Jason

[email protected]

1-702-714-7001Extn: 9043

Genetics & Molecular Biology Journals

Anna Melissa

[email protected]

1-702-714-7001Extn: 9006

Immunology & Microbiology Journals

David Gorantl

[email protected]

1-702-714-7001Extn: 9014

Materials Science Journals

Rachle Green

[email protected]

1-702-714-7001Extn: 9039

Nursing & Health Care Journals

Stephanie Skinner

[email protected]

1-702-714-7001Extn: 9039

Medical Journals

Nimmi Anna

[email protected]

1-702-714-7001Extn: 9038

Neuroscience & Psychology Journals

Nathan T

[email protected]

1-702-714-7001Extn: 9041

Pharmaceutical Sciences Journals

Ann Jose

[email protected]

1-702-714-7001Extn: 9007

Social & Political Science Journals

Steve Harry

[email protected]

1-702-714-7001Extn: 9042

© 2008- 2018 OMICS International - Open Access Publisher. Best viewed in Mozilla Firefox | Google Chrome | Above IE 7.0 version
Leave Your Message 24x7